Table 2.
Independent correlates of incident T2DM, as defined by a reduced multivariable model.
| Factors in the final modela | n (%) | Adjusted ORb | 95% CIb | P-value |
|---|---|---|---|---|
| Sex | ||||
| Men | 3,063 (77.1) | Ref. | – | |
| Women | 886 (22.3) | 1.47 | 1.13-1.93 | 0.005 |
| Transgenders | 22 (0.55) | 1.23 | 0.16-9.71 | >0.50 |
| BMI at incident DM or last visit (missing 364) | ||||
| <25 (kg/m2) | 1,406 (38.9) | Ref. | – | |
| 25–29 (kg/m2) | 1,168 (32.4) | 1.46 | 1.01-2.10 | 0.043 |
| ≥30 (kg/m2) | 1,033 (28.7) | 3.36 | 2.40-4.70 | <0.0001 |
| Nadir CD4+ T-cell counta in the last 24 months | ||||
| <200 cells/µl | 931 (23.4) | 1.02 | 0.69-1.49 | >0.50 |
| 200–500 cells/µl | 1,374 (34.6) | 1.40 | 1.06-1.42 | 0.020 |
| >500 cells/µl | 1,666 (42.0) | Ref. | – | |
| Highest plasma viral loada in the last 24 months | ||||
| <200 | 2,273 (57.2) | Ref. | – | |
| 200–23,596 (Q3) | 705 (17.8) | 2.24 | 1.64-3.05 | <0.0001 |
| >23,596 | 993 (25.0) | 2.21 | 1.55-3.15 | <0.0001 |
| Duration of statin use | ||||
| No use | 2,864 (72.1) | Ref | – | |
| Use for <6 months | 145 (3.7) | 8.92 | 5.87-13.58 | <0.0001 |
| Use ≥6 months | 962 (24.3) | 10.21 | 7.71-13.53 | <0.0001 |
aAt least one entry in each categorical variable has shown independent association with T2DM (adjusted P < 0.05).
bThe odds ratio (OR) and 95% confidence interval have been adjusted for all factors in the model, as well as age, race, study enrollment dates, exposure to HIV-1 protease inhibitors, and statin groups (atorvastatin, lovastatin, and simvastatin as lipophilic; pravastatin, rosuvastatin, and fluvastatin as hydrophilic). For comparisons involve multiple categories within a specific variable, the group with the largest sample size is set as the norm/reference.